Bacillus calmette—Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results
Open Access
- 15 January 1995
Abstract
Background. Intravesical instillation therapy of Bacillus Calmette‐Guérin (BCG) has become a standard treatment for carcinoma in situ (CIS) of the urinary bladder. However, there have been few reports concerning the direct effect of BCG on existing tumors classified as Ta or T1. In the first stage of this clinical study, 157 patients were treated with BCG intravesical instillation (Tokyo 172 strain [BCG Co. Ltd., Tokyo, Japan]; 80 mg weekly for eight times) by our Study Group. The efficacy on existing tumors was a complete response (CR) rate of 84.4% and 66.4% and a partial response (PR) of 6.3% and 20.8% for 32 cases of CIS and 125 cases of Ta or T1 tumors, respectively. Methods. In the second stage of this study, the authors investigated the outcome of the 138 patients who had achieved CR or PR in the first stage. One hundred twenty (87.0%) of the patients were followed fully. Of those patients, 52 were randomized to receive prophylactic (maintenance) therapy consisting of BCG of 40 mg monthly for 12 times (Group A), whereas 55 were randomized to an untreated control group (Group B). Thirteen other patients refused to be randomized and were followed without prophylactic instillation. Results. The median follow‐up period was 48 months for Group A and 42 months for Group B. In Groups A and B, the beneficial effect of the BCG therapeutic instillation persisted for a long time, and the 3‐year nonrecurrence rate was 77.6% in Group A and 74.2% in Group B. Disease progression was observed rarely. Conclusion. For patients in whom transurethral resection of tumors of the bladder (TUR‐Bt) alone is unlikely to eliminate the tumor, intravesical BCG is potentially the treatment of choice. Cancer 1995;75:552‐9.Keywords
This publication has 14 references indexed in Scilit:
- Optimal BCG Treatment of Superficial Bladder Cancer as Defined by American TrialsEuropean Urology, 1992
- A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the BladderNew England Journal of Medicine, 1991
- A Low Dose Bacillus Calmette-Guerin Regimen in Superficial Bladder Cancer Therapy: Is it Effective?Journal of Urology, 1991
- Multicenter study of superficial bladder cancer treated with intravesical bacillus Calmette-Guérin or adriamycinUrology, 1990
- Superficial Bladder Cancer Treated with Bacillus Calmette-Guerin: A Multivariate Analysis of Factors Affecting Tumor ProgressionJournal of Urology, 1989
- Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancerCancer Chemotherapy and Pharmacology, 1987
- Bacillus Calmette-Guerin for Superficial Transitional Cell Carcinoma of the BladderJournal of Urology, 1986
- The Use of Bacillus Calmette-Guerin in the Therapy of Bladder Carcinoma in SituJournal of Urology, 1985
- Experience with Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, 1982
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976